We are live on ! Find out more
NVET

Nexvet Biopharma plc Ordinary Shares
NVET

Delisted

NVET was delisted on the 28th of July, 2017.

Back to rankings

17 hedge funds and large institutions have $50.7M invested in Nexvet Biopharma plc Ordinary Shares in 2015 Q1 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
17
Holders Change
+17
Holders Change %
–
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$23.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$8.28M
4
FCMI
Foresite Capital Management II
California
+$6.7M
5
Jennison Associates
Jennison Associates
New York
+$4.39M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$20.1M +$23.7M +2,499,996 New
Wellington Management Group
2
Wellington Management Group
Massachusetts
$10.6M +$12.5M +1,322,870 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$7.03M +$8.28M +875,000 New
FCMI
4
Foresite Capital Management II
California
$5.69M +$6.7M +708,332 New
Jennison Associates
5
Jennison Associates
New York
$3.72M +$4.39M +463,506 New
ACPU
6
Arrowgrass Capital Partners (US)
Delaware
$2.15M +$2.53M +267,500 New
Norges Bank
7
Norges Bank
Norway
$361K +$426K +45,000 New
CC
8
CQS Cayman
Cayman Islands
$281K +$331K +35,000 New
Bank of America
9
Bank of America
North Carolina
$237K +$279K +29,524 New
Goldman Sachs
10
Goldman Sachs
New York
$156K +$183K +19,379 New
Millennium Management
11
Millennium Management
New York
$153K +$180K +19,000 New
SIM
12
Spark Investment Management
New York
$123K +$160K +16,900 New
Deutsche Bank
13
Deutsche Bank
Germany
$82K +$96.7K +10,220 New
Morgan Stanley
14
Morgan Stanley
New York
$37K +$44.3K +4,677 New
Citigroup
15
Citigroup
New York
$13K +$15.1K +1,600 New
UBS Group
16
UBS Group
Switzerland
$5K +$6.31K +667 New
TRCT
17
Tower Research Capital (TRC)
New York
$1K +$1.47K +155 New

NVET Hedge Fund Activity: Q1 2015 in Review

17 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q1 2015, worth a combined $50.7M.

Buyers outnumbered sellers: 17 funds opened new NVET positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $23.7M.

  • 17 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q1 2015, up from 0 in Q4 2014.
  • Funds reported $50.7M of Nexvet Biopharma plc Ordinary Shares stock for Q1 2015.
  • 17 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q1 2015 and 0 closed out, a net change of +17 holders.
  • The largest Nexvet Biopharma plc Ordinary Shares buyer in Q1 2015 was Farallon Capital Management, an estimated $23.7M added.

Based on aggregated 13F filings for Q1 2015.